198 related articles for article (PubMed ID: 32685584)
21. The Association between Adenotonsillectomy and Frequency of Vaso-Occlusive Crises in Patients with Sickle Cell Disease.
Marzouki HZ; Abdalwassie LK; Tallab MA; Al-Khatib T; Safdar OY; Alzharani F; Alsiny F; Farsi NJ
Indian J Otolaryngol Head Neck Surg; 2022 Dec; 74(Suppl 3):5499-5505. PubMed ID: 36742879
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
23. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
Coyne KS; Currie BM; Callaghan M; Wyrwich KW; Pease S; Baker CL; Arkin S; Pittman DD
Eur J Haematol; 2022 Sep; 109(3):226-237. PubMed ID: 35569114
[TBL] [Abstract][Full Text] [Related]
24. Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care.
Allen Liles E; Kirsch J; Gilchrist M; Adem M
Hosp Pract (1995); 2014 Apr; 42(2):70-6. PubMed ID: 24769786
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
26. The Burden of Sickle Cell Disease on Children and Their Caregivers: Caregiver Reports of Children's Health-Related Quality of Life and School Experiences, Caregiver Burden, and Their Association with Frequency of Vaso-Occlusive Crises.
Campbell A; Rizio AA; McCausland KL; Iorga S; Yen GP; Paulose J; Lee S
Patient Relat Outcome Meas; 2023; 14():369-381. PubMed ID: 38046665
[TBL] [Abstract][Full Text] [Related]
27. Hospitalization Events Among Adolescents and Adults With Sickle Cell Disease in a Tertiary Care Center in Central India.
Wasnik P; Das P; Kumar A; Kannauje PK; R R; Pandit V; Sahu T; Sahu J
Cureus; 2024 May; 16(5):e61185. PubMed ID: 38933640
[TBL] [Abstract][Full Text] [Related]
28. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.
Osunkwo I; Manwani D; Kanter J
Ther Adv Hematol; 2020; 11():2040620720955000. PubMed ID: 33062233
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
30. Sickle cell disease as a vascular disorder.
Ofori-Acquah SF
Expert Rev Hematol; 2020 Jun; 13(6):645-653. PubMed ID: 32362160
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees.
Mahesri M; Schneeweiss S; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Desai RJ
Eur J Haematol; 2021 Feb; 106(2):273-280. PubMed ID: 33155319
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide: A potential etiological agent for vaso-occlusive crises in sickle cell disease.
Gupta P; Kumar R
Nitric Oxide; 2024 Mar; 144():40-46. PubMed ID: 38316197
[TBL] [Abstract][Full Text] [Related]
33. Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014.
Sharma P; McCarty TR; Yadav S; Ngu JN; Njei B
Obes Surg; 2019 Jun; 29(6):1789-1796. PubMed ID: 30805858
[TBL] [Abstract][Full Text] [Related]
34. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal assessment of adhesion to vascular cell adhesion molecule-1 at steady state and during vaso-occlusive crises in sickle cell disease.
White J; Callaghan MU; Gao X; Liu K; Zaidi A; Tarasev M; Hines PC
Br J Haematol; 2022 Feb; 196(4):1052-1058. PubMed ID: 34850378
[TBL] [Abstract][Full Text] [Related]
37. Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.
Lamarre Y; Romana M; Waltz X; Lalanne-Mistrih ML; Tressières B; Divialle-Doumdo L; Hardy-Dessources MD; Vent-Schmidt J; Petras M; Broquere C; Maillard F; Tarer V; Etienne-Julan M; Connes P
Haematologica; 2012 Nov; 97(11):1641-7. PubMed ID: 22689686
[TBL] [Abstract][Full Text] [Related]
38. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
[TBL] [Abstract][Full Text] [Related]
39. Weight Loss as an Effective Strategy to Decrease Opioid Use and Frequency of Vaso-Occlusive Crises in Patients with Sickle Cell Disease.
Babroudi S; Vesel T
J Palliat Med; 2021 Apr; 24(4):632-634. PubMed ID: 32881637
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
